0 %

DNA Analysis

The advances in treatments have made it possible to include new genetic diseases to the panel of diseases eligible for neonatal screening. These diseases can be detected by finding the site of the specific DNA mutation.

LaCAR is developing its range and expanding its technology portfolio by adding qPCR to its already reputed enzyme range. The DNA analysis range includes kits for first-line neonatal screening suitable for the use of dried blood samples.

LaCar
The NEONATAL SCID&SMA Screening qPCR Flex kit is an assay intended for the semi-quantitative determination of TREC, aiding in the screening of newborns for Severe Combined Immunodeficiency (SCID), and for the qualitative detection of the SMN1 gene (Exon 7), aiding in the screening of newborns for Spinal Muscular Atrophy (SMA).
LaCar
The SMA Screening solutions offered by LaCAR are CE-IVDR diagnostic assays designed for the qualitative detection of the SMN1 gene (Exon 7), supporting the screening of newborns for Spinal Muscular Atrophy (SMA).
LaCar
The NEONATAL SCID Screening qPCR Flex Kit is a CE-IVDR-certified assay developed for newborn screening, providing semi-quantitative TREC analysis to aid in the detection of Severe Combined Immunodeficiency (SCID) in dried blood sample of neonates on 903® or 226 blotting paper.
Categories

You have a question regarding our products ? You want to know more about our method ?

Find out about our other expertises

Genetic testing CE Kits
Pharmacogenetics
Contact